Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | PRCP | P42785 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634059 | 0.86 | GRIN1 (0.84) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| SCHEMBL28282384 | 0.84 | GRIN1 (0.88) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| SCHEMBL30364176 | 0.82 | SIGMAR1 (0.77) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| SCHEMBL3413521 | 0.80 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3407425 | 0.78 | OPRL1 (0.56) | OPRL1OPRM1OPRK1 | |
| Phencyclidine SCHEMBL17008793 | 0.78 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| SCHEMBL9153279 | 0.78 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| Phencyclidine SCHEMBL42022 | 0.78 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| Rolicyclidine SCHEMBL517928 | 0.78 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BCYP2B6SLC6A2 | |
| SCHEMBL3407014 | 0.78 | OPRM1 (0.98) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502907-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2018-08-29 | — | — | EP | claimed |
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | claimed |
| EP-2502907-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-09-26 | — | — | EP | claimed |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2012-08-09 | — | — | US | claimed |
| EP-2260021-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | claimed |
| WO-2009118168-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | claimed |
| EP-2502907-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| EP-2518052-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9580386-B2 | Substituted 4-aminocyclohexane derivatives | GRÜNENTHAL (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9403767-B2 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8835689-B2 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2518052-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| EP-2502907-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| EP-2260021-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| WO-2009118168-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | SIGMAR1 9/4885GRIN2D 240/4885GRIN3B 102/4885 |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | SIGMAR1 9/4885GRIN2D 240/4885GRIN3B 102/4885 |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | SIGMAR1 9/4885GRIN2D 240/4885GRIN3B 102/4885 |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | SIGMAR1 9/4885GRIN2D 240/4885GRIN3B 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.